Neurofeedback and Depression: A Winning Combination?

Depression affects more than 300 million people worldwide and is projected to become the leading cause of disease burden by 2030. Antidepressants remain the frontline treatment, yet up to one-third of patients fail to respond adequately. This leaves a major gap in care — and an urgent need for effective adjunctive therapies.

New emerging research from the University Clinic of Psychiatry in Skopje, North Macedonia, explores just such an approach. The study investigated whether combining standard antidepressant medication with EEG-based neurofeedback could accelerate and deepen recovery for patients with affective disorders.

Neurofeedback is a non-invasive technique that provides real-time feedback on brain activity, teaching the brain to regulate itself. Rooted in the principle of neuroplasticity, this method allows patients to learn how to shift dysfunctional patterns into more adaptive ones. Integrating neurofeedback into depression treatment represents a move toward more personalized, active, and patient-centered care.

Methods

A prospective, randomized controlled study was conducted with 100 outpatients aged 18–65, all diagnosed with affective disorders under ICD-10 codes F32 (depressive episode), F33 (recurrent depressive disorder), or F34 (persistent mood disorder).

Participants were randomly divided into two groups:

• Study Group (n = 50): received antidepressant therapy + 10 sessions of alpha/theta neurofeedback using the Encephalan-EEGR-19/26 system with Rehacor software. Each session lasted 25 minutes.

• Control Group (n = 50): received antidepressant monotherapy only.

Neurofeedback sessions targeted alpha (8–12 Hz) and theta (4–8 Hz) activity, aiming to promote deep relaxation, reduce cortical hyperactivation, and enhance emotional regulation.

Assessment tools included:

• Beck Depression Inventory (BDI): patient-reported symptom severity.

• Clinical Global Impression (CGI): clinician-rated global severity and improvement.

Evaluations occurred at baseline and then every 4 weeks over a 6-month period.

Results

Patients receiving neurofeedback in addition to medication showed faster and greater symptom reduction compared to those receiving medication alone.

• At baseline: both groups had comparable depression severity (BDI: 18.9 vs. 21.0, p = 0.15).

• After 2 months: the neurofeedback group showed an 11% reduction in BDI scores, compared to just 2% in the control group (p = 0.013).

• At 6 months:

  • BDI: 13.14 (NF) vs. 19.58 (control), p < 0.0001

  • CGI: 7.34 (NF) vs. 9.54 (control), p < 0.0001

The study confirmed a statistically and clinically significant advantage for the combined treatment, with earlier response and greater long-term improvement.

Discussion

This research reinforces what many clinicians already observe: neurofeedback is not just supportive therapy — it can reshape treatment trajectories in depression. Antidepressants act broadly on neurotransmitter systems, while neurofeedback provides targeted training of brain network dynamics, enabling patients to actively regulate their own brain activity.

The benefits of integration include:

• Faster symptom reduction — quicker relief in the early weeks of treatment.

• Active engagement — patients become participants rather than passive recipients.

• Safety and compatibility — neurofeedback has no pharmacological side effects and complements medication.

• Potential long-term resilience — by strengthening self-regulation, improvements may sustain beyond treatment.

Brendan’s Perspective

I have to admit — studies like this make my heart beat a little faster. Clinically, these are often the patients who walk into my office depleted, discouraged, and told to “wait it out” on yet another medication trial. But with neurofeedback, something shifts. They see — quite literally — that their brain is capable of change.

The alpha/theta protocol is a powerful tool. By working at the border of wakefulness and deep relaxation, it fosters a hypnagogic state that softens cognitive defenses and enables emotional reprocessing. I often see it as a beneficial protocol for:

• Chronic or recurrent depression, especially when rumination is high.

• PTSD, particularly in stabilization phases.

• Resistant insomnia linked to hyperarousal.

But depression isn’t one-size-fits-all, and neither is neurofeedback. Active protocols can also be crucial: increasing low beta to enhance focus and drive, inhibiting high beta to calm anxious overactivation, reducing excess slow-wave activitythat can trap patients in fatigue and lethargy, or stimulating SMR to consolidate sleep and restore restorative rhythms. Even supporting delta activity, when it is deficient, can lift the heavy fog of lack of motivation and chronic tiredness. These variations make neurofeedback a highly adaptable therapeutic tool, one that meets the brain where it is.

Contrast this with antidepressants: widely prescribed, but their response rates are far from stellar — with much of their effect explained by placebo responses and expectancy rather than consistent biological impact. Neurofeedback offers something different: an active, learning-based process where progress is visible, measurable, and empowering.

In practice, I personalize the protocol: adjusting frequency thresholds, selecting electrode sites, and tailoring based on qEEG findings. I always pair it with psychoeducation, so patients recognize internal shifts and build resilience outside the lab.

This study confirms what many of us have long practiced: the future of mental health lies not in “either/or” but in “both/and.” Chemical support and functional learning. Medication and neuroplasticity. Passive relief and active regulation.

Conclusion

The evidence is compelling: combining neurofeedback with antidepressants enhances treatment outcomes in affective disorders. Faster improvements, stronger long-term effects, and greater patient engagement make this approach a valuable addition to modern psychiatry.

Is neurofeedback a miracle cure? No. But it is one of the most promising tools we have to integrate into holistic, neuroscience-informed, patient-centered care.

Reference

Risteski, A., Arsova, S., & Mitrovska, S. (2025). Quantitative analysis of the efficacy of treatment with neurofeedback method in patients with affective disorders. Academic Medicine Journal, 5(2), 73–82.